Literature DB >> 20331633

Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma.

Reiko Nakai1, Yoshimasa Maniwa, Yugo Tanaka, Wataru Nishio, Masahiro Yoshimura, Yutaka Okita, Chiho Ohbayashi, Naoyuki Satoh, Hisakazu Ogita, Yoshimi Takai, Yoshitake Hayashi.   

Abstract

Nectin-like molecule-5 (Necl-5) is an immunoglobulin (Ig)-like molecule that is up-regulated in many types of cancer cells. It was shown experimentally that Necl-5 enhances cell migration, proliferation, and metastasis, but its clinical significance has not been documented. The aim of this study was to observe the expression of Necl-5 in surgically resected primary lung adenocarcinomas and to investigate its clinical significance. A total of 63 surgically resected primary pulmonary adenocarcinoma tissues were investigated by immunohistochemistry for the expression of Necl-5. The relationship between expression of Necl-5 and clinicopathological features was analyzed, and the influence of Necl-5 expression on outcomes in these patients was assessed. A strong expression of Necl-5 by cancer cells was observed in 43 of the 63 tumors. The overexpression of Necl-5 by cancer cells was significantly associated with lymph node metastasis (P = 0.0398), TNM staging (P = 0.0367), and the bronchioloalveolar carcinoma ratio of tumors (P = 0.0423). Furthermore, the disease-free survival rate in patients with positive Necl-5 overexpression was significantly lower than that in patients with negative Necl-5 overexpression (P = 0.0004). Multivariate survival analysis revealed Necl-5 expression to be an independent risk factor for an unfavorable outcome (P = 0.0294). Additionally, an analysis including only the stage I cases revealed that the disease-free survival rate of the Necl-5-positive group was significantly lower than that of the Necl-5-negative group (P = 0.0192). These results indicate that Necl-5 plays a role in mediating tumor cell invasion and that the overexpression of Necl-5 in cancer cells has clinical significance for prognostic evaluation of patients with primary pulmonary adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20331633     DOI: 10.1111/j.1349-7006.2010.01530.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  55 in total

1.  Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells.

Authors:  Sebastian Seth; Quan Qiu; Simon Danisch; Michael K Maier; Asolina Braun; Inga Ravens; Niklas Czeloth; Rebecca Hyde; Oliver Dittrich-Breiholz; Reinhold Förster; Günter Bernhardt
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade.

Authors:  Bo Ryeong Lee; Sehyun Chae; Jihyun Moon; Myeong Joon Kim; Hankyu Lee; Hyuk Wan Ko; Byoung Chul Cho; Hyo Sup Shim; Daehee Hwang; Hye Ryun Kim; Sang-Jun Ha
Journal:  JCI Insight       Date:  2020-07-23

3.  Anticancer activity of emodin is associated with downregulation of CD155.

Authors:  Liang Fang; Fang Zhao; Stephen Iwanowycz; Junfeng Wang; Sophia Yin; Yuzhen Wang; Daping Fan
Journal:  Int Immunopharmacol       Date:  2019-07-17       Impact factor: 4.932

4.  Oncolytic poliovirus against malignant glioma.

Authors:  Christian Goetz; Elena Dobrikova; Mayya Shveygert; Mikhail Dobrikov; Matthias Gromeier
Journal:  Future Virol       Date:  2011-09       Impact factor: 1.831

Review 5.  Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer.

Authors:  Hauke Stamm; Jasmin Wellbrock; Walter Fiedler
Journal:  Mamm Genome       Date:  2018-08-21       Impact factor: 2.957

Review 6.  Balancing natural killer cell activation through paired receptors.

Authors:  Ludovic Martinet; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2015-03-06       Impact factor: 53.106

7.  Overexpression of CD155 relates to metastasis and invasion in osteosarcoma.

Authors:  Baobiao Zhuo; Yuan Li; Feng Gu; Zhengwei Li; Qingzeng Sun; Yingchun Shi; Yang Shen; Fengfei Zhang; Rong Wang; Xiaodong Wang
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

Review 8.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

9.  Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients.

Authors:  Sun Min Lim; Min Hee Hong; Sang-Jun Ha; Daehee Hwang; Sehyun Chae; Yoon Woo Koh; Eun Chang Choi; Se-Heon Kim; Da-Hee Kim; Sun Och Yoon; Hye Ryun Kim
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-22       Impact factor: 4.553

Review 10.  Oncolytic polio virotherapy of cancer.

Authors:  Michael C Brown; Elena Y Dobrikova; Mikhail I Dobrikov; Ross W Walton; Sarah L Gemberling; Smita K Nair; Annick Desjardins; John H Sampson; Henry S Friedman; Allan H Friedman; Douglas S Tyler; Darell D Bigner; Matthias Gromeier
Journal:  Cancer       Date:  2014-06-17       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.